
Please try another search
Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology and chemistry by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery in the United States. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers. Its preclinical stage product includes RBM39 to treat HR-proficient ovarian cancer. The company has collaboration and agreement with Bayer AG; the University of Utah Research Foundation; Ohio State Innovation Foundation; Roche & Genentech; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.
Name | Age | Since | Title |
---|---|---|---|
Christopher C. Gibson | 41 | 2013 | Co-Founder, CEO & Director |
Robert M. Hershberg | 62 | 2020 | Independent Chairman |
H. Perry Fell | 67 | 2014 | Member of Business Advisory Panel |
Zachary S. Bogue | 50 | 2018 | Independent Director |
Dean Y. Li | 61 | 2013 | Independent Director |
Joseph P. Miletich | 73 | 2021 | Chairman of Therapeutics Advisory Board |
Zavain Dar | 36 | 2016 | Independent Director |
Kirk R. Thomas | - | 2014 | Member of Scientific & Technical Advisory Board |
Anne Carpenter | - | 2014 | Member of Scientific and Technical Advisory Board |
Blake C. Borgeson | 43 | 2013 | Independent Director |
Elaine D. Sun | 53 | 2025 | Independent Director |
Franziska Michor | 43 | 2024 | Independent Director |
Namandje Bumpus | 44 | 2025 | Independent Director |
Najat Khan | 41 | 2024 | Chief R&D Officer, Chief Commercial Officer and Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review